shenzhen salubris pharmaceuticals co., ltd.-金沙贵宾厅
join us
金沙贵宾厅-优惠大厅-js555888金沙
home page
about us
profile
affiliates/subsidiaries
development history
quality management
contact us
legal statement
science and technology
r&d platform
r&d pipeline
therapeutic field
international business
apis
finished products
medical device
download product list
contact
news center
news & trends
public information
news & trends
04
2022-03
nmpa approves clinical trials with sal0114 tablets for ad agitation
17
2022-02
salubris announces clinical trial approval of sal0114 tablet – potential clinical depression treatment candidate
17
2022-02
completion of clinical enrollment for phase iii clinical trial of sal0107 project – potential hypertension treatment candidate
21
2021-06
allisartan isoproxil indapamide sustained-release tablets was approved for clinical trials
recently, salubris received the notice of approval of clinical trials approved and issued by national medical products administration, which means that salubris was approved to carry out clinical trials of allisartan isoproxil indapamide sustained-re
14
2021-01
significant progress has been made in the application for clinical trials of two compound antihypertensive drugs of salubris
recently, salubris received the notice of approval of clinical trials approved and issued by national medical products administration, which means that salubris was approved to carry out clinical trials of "allisartan isoproxil amlodipine besylate t
21
2020-09
salubris's new drug for chronic heart failure, sal007,was approved for clinical trial in china
sal007 is expected to provide a new choice for the treatment of chronic heart failure, and bring new hope to the extensive patients with chronic heart failure.
目前在第
1
页,
共有
3
页,
共有
17
条记录
1
2
3
下一页
最后一页
跳转到
页
网站地图